Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 44847 in Type 2 Diabetes
NCT02211963Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2007
- Primary completion
- Jun 2007
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing BI 44847 with Placebo (2 arms). Primary endpoints: Number of patients with adverse events up to 53 days, Number of patients with clinically significant findings in vital signs up to 18 days and 3 more. Started Feb 2007; status: completed.
02
Drugs
BI-44847
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02211963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02211963.